Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Hospira, Inc. |
---|---|
Information provided by: | Hospira, Inc. |
ClinicalTrials.gov Identifier: | NCT00216190 |
The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine in ICU subjects that are initially intubated, mechanically ventilated and require sedation for greater tha 24 hours.
Condition | Intervention | Phase |
---|---|---|
Mechanically Ventilated and Intubated Subjects |
Drug: Dexmedetomidine, Midazolam |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | "A Phase 4, Randomized, Double-Blind, Multi-Center, Comparator Study Evaluating the Safety and Efficacy of Dexmedetomidine Compared to IV Midazolam in ICU Subjects Requiring Greater Than Twenty-Four Hours of Continuous Sedation" |
Estimated Enrollment: | 375 |
Study Start Date: | March 2005 |
Study Completion Date: | August 2007 |
Traditional agents such benzodiazepines and propofol have long been used to sedate critically ill patients. Unfortunately, these agents have serious disadvantages that may have a negative impact on patient outcomes. These disadvantages include respiratory depression, prolonged mechanical ventilation, paradoxical agitation, myocardial depression, hypotension, tachyphylaxis, physical dependence, and an unpredictable duration of action following long term infusions. Additionally, concomitant use of an opioid or other analgesic is often required for ICU patients to achieve adequate levels of pain relief, which may also prolong awakening and possibly increase respiratory depression.
Dexmedetomidine may offer a new treatment option that remedies many of the deficiencies of traditional sedatives. This agent would provide for accurate, titratable sedation and analgesia without the concurrent respiratory depression and accumulation common to other agents. It may permit greater patient interaction due to reduced impairment of cognition and may reduce risks associated with opioids due to its analgesia sparing property. Although such a drug may have important benefits for ICU patients requiring sedation for greater than 24 hours, dexmedetomidine is not currently approved for such long-term usage.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | 2001-001 |
Study First Received: | August 31, 2005 |
Last Updated: | September 20, 2007 |
ClinicalTrials.gov Identifier: | NCT00216190 |
Health Authority: | United States: Food and Drug Administration |
Sedation, ICU, Anesthesia, Dexmedetomidine, Midazolam |
Dexmedetomidine Midazolam |
Anesthetics, Intravenous Neurotransmitter Agents Adrenergic alpha-Agonists Tranquilizing Agents Adrenergic Agents Molecular Mechanisms of Pharmacological Action GABA Modulators Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Anesthetics Adrenergic Agonists |
Pharmacologic Actions Adjuvants, Anesthesia Sensory System Agents Analgesics, Non-Narcotic Anesthetics, General Therapeutic Uses Hypnotics and Sedatives GABA Agents Anti-Anxiety Agents Peripheral Nervous System Agents Analgesics Central Nervous System Agents |